Aug. 14 Clinical Quick Takes: Lynparza boosts ovarian cancer survival in first-line setting; plus Novavax, Gritstone and Solid

Lynparza extends PFS in first-line ovarian cancer
Lynparza olaparib plus bevacizumab as first-line maintenance therapy met the primary endpoint of significantly extending progression-free survival (PFS) vs. standard-of-care bevacizumab alone in advanced ovarian

Read the full 315 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE